in-Pharma Technologist -- Teva has withdrawn its lansoprazole delayed-release ODT formulation after reports it blocked oral syringes and feeding tubes. Orally disintegrating tablet (ODT) formulations of lansoprazole sold by Teva can be administered as a suspension through oral syringes and feeding tubes. However, the US Food and Drug Administration (FDA) has received reports the product has been associated with blocked tubes.
